Search
for
Sort by
Research 31–60 of 1000+
- Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Environmental Modulation of JAK3-Mediated Immune Dysregulation in Alopecia Areata
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- New drugs under investigation for the treatment of alopecias
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
- Psychophysiological Mechanisms of Stress Impact on Hair Loss Processes
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Alopecia areata – Current understanding and management
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Baricitinib for the Treatment of Alopecia Areata
- Baricitinib in the Management of Coexisting Alopecia Areata and Atopic Dermatitis: A Case Report
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Diagnostic Challenges and Treatment Strategies in Neutrophilic Cicatricial Alopecias: A Narrative Review from Conventional Therapies to New Therapeutic Targets
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Cytokine-targeted treatment in alopecia areata - new possibilities?
- Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes
- Emerging Topical and Systemic JAK Inhibitors in Dermatology